SBIR Topic 097, Phase II - Early Detection and Monitoring of Cardiac Injury Due to Cardiotoxicity

该合同的目标是鼓励创新方法的发展，通过微创手段尽早检测和监测癌症治疗引起的心脏损伤。心脏损伤的早期监测将提高心脏的安全性和癌症治疗的疗效。承包商将开发一种微创和快速心血管毒性血液检测设备，以监测接受化疗的癌症患者。该设备是一种手持式，视觉读数，半定量测定心脏肌钙蛋白I （TnI）和b型利钠蛋白（BNP）。

The goal of this contract is to encourage the development of innovative methods to detect and monitor cancer therapy-induced cardiac injury as early as possible through minimally invasive means. Early monitoring of cardiac injury will enhance both cardiac safety and treatment efficacy of cancer therapies. The contractor will develop a minimally invasive and rapid cardiovascular toxicity blood test device to monitor cancer patients undergoing chemotherapies. The device is a handheld, visual readout, semi-quantitative assay for measuring cardiac troponin I (TnI) and B-type natriuretic protein (BNP).